• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice.

作者信息

Booth Christopher M

机构信息

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, and Departments of Oncology and Public Health Sciences, Queen's University, Kingston, ON, Canada.

出版信息

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):31-2. doi: 10.5489/cuaj.3600.

DOI:10.5489/cuaj.3600
PMID:26977203
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4771555/
Abstract
摘要

相似文献

1
Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice.肌层浸润性膀胱癌的围手术期化疗：弥合证据与实践之间的差距
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):31-2. doi: 10.5489/cuaj.3600.
2
Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.将围手术期化疗纳入肌肉浸润性膀胱癌治疗：策略与现实
J Natl Compr Canc Netw. 2009 Jan;7(1):40-7. doi: 10.6004/jnccn.2009.0003.
3
Why is perioperative chemotherapy for bladder cancer underutilized?为什么膀胱癌的围手术期化疗未得到充分利用？
Urol Oncol. 2014 May;32(4):391-5. doi: 10.1016/j.urolonc.2013.11.003. Epub 2014 Feb 6.
4
Muscle invasive bladder cancer: closing the gap between practice and evidence.肌层浸润性膀胱癌：弥合实践与证据之间的差距。
Minerva Urol Nefrol. 2015 Mar;67(1):65-73. Epub 2014 Nov 26.
5
Perioperative chemotherapy for localized bladder cancer.局限性膀胱癌的围手术期化疗
Can J Urol. 2006 Feb;13 Suppl 1:77-80.
6
Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.新辅助化疗在肌肉浸润性膀胱癌治疗中的应用：弥合证据与实践之间的差距
Urol Clin North Am. 2015 May;42(2):181-7, viii. doi: 10.1016/j.ucl.2015.01.002. Epub 2015 Mar 5.
7
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study.肌层浸润性膀胱癌的围手术期化疗：基于人群的结局研究。
Cancer. 2014 Jun 1;120(11):1630-8. doi: 10.1002/cncr.28510. Epub 2014 Apr 14.
8
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.1998年至2003年III期膀胱癌围手术期化疗的低发生率：来自国家癌症数据库的报告。
J Urol. 2007 Aug;178(2):451-4. doi: 10.1016/j.juro.2007.03.101. Epub 2007 Jun 11.
9
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.机器人辅助与开放性根治性膀胱切除术在接受围手术期化疗的肌层浸润性膀胱癌患者中的比较：多中心研究中肿瘤学家的观点。
Eur Urol Focus. 2018 Dec;4(6):937-945. doi: 10.1016/j.euf.2017.03.011. Epub 2017 Mar 31.
10
The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.膀胱切除术以及围手术期使用甲氨蝶呤、长春花碱、阿霉素和顺铂化疗对肌层浸润性膀胱癌患者复发风险及复发模式的影响。
J Urol. 2000 May;163(5):1413-8.

引用本文的文献

1
Advances in surgical management of muscle invasive bladder cancer.肌肉浸润性膀胱癌外科治疗进展
Indian J Urol. 2017 Apr-Jun;33(2):106-110. doi: 10.4103/0970-1591.203416.

本文引用的文献

1
Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: a population-based study.淋巴结计数是膀胱癌手术治疗质量的有效指标：一项基于人群的研究。
Urol Oncol. 2015 Oct;33(10):425.e15-23. doi: 10.1016/j.urolonc.2015.06.005. Epub 2015 Jul 18.
2
Benefits of Adjuvant Chemotherapy for Bladder Cancer.辅助化疗对膀胱癌的益处。
JAMA Oncol. 2015 Sep;1(6):727-8. doi: 10.1001/jamaoncol.2015.1210.
3
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.根治性膀胱切除术治疗 pT3-pT4 或 N+M0 膀胱尿路上皮癌患者中即刻与延迟化疗的比较（EORTC 30994）：一项国际多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.
4
Processes of care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer.护理过程及手术量对癌症特异性生存的影响：一项基于人群的膀胱癌研究。
Urology. 2014 Nov;84(5):1049-57. doi: 10.1016/j.urology.2014.06.070. Epub 2014 Oct 24.
5
Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study.常规临床实践中膀胱癌的根治性治疗：一项基于人群的结局研究。
Clin Oncol (R Coll Radiol). 2014 Aug;26(8):506-14. doi: 10.1016/j.clon.2014.05.007. Epub 2014 Jun 20.
6
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study.肌层浸润性膀胱癌的围手术期化疗：基于人群的结局研究。
Cancer. 2014 Jun 1;120(11):1630-8. doi: 10.1002/cncr.28510. Epub 2014 Apr 14.
7
Why is perioperative chemotherapy for bladder cancer underutilized?为什么膀胱癌的围手术期化疗未得到充分利用？
Urol Oncol. 2014 May;32(4):391-5. doi: 10.1016/j.urolonc.2013.11.003. Epub 2014 Feb 6.
8
Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.局部和局部晚期肌层浸润性膀胱癌围手术期化疗的使用趋势：潮流转变的迹象
Eur Urol. 2015 Jan;67(1):165-170. doi: 10.1016/j.eururo.2014.01.009. Epub 2014 Jan 23.
9
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.新辅助化疗应给予符合条件的新诊断的、潜在可切除的膀胱肌层浸润性尿路上皮癌（MIBC）患者：2013年CAGMO共识声明及简化转诊流程呼吁。
Can Urol Assoc J. 2013 Sep-Oct;7(9-10):312-8. doi: 10.5489/cuaj.1506.
10
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.浸润性膀胱癌辅助化疗：2013 年更新的随机试验系统评价和荟萃分析。
Eur Urol. 2014 Jul;66(1):42-54. doi: 10.1016/j.eururo.2013.08.033. Epub 2013 Aug 28.